“These data provide support for administration of commercially available antibodies targeting the truncated EGFR domain on the surface of JCAR017 to reduce/eliminate the CAR T cells in vivo, if necessary.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Biodistribution & persistence
No biodistribution studies; persistence assessed in xenograft PD study
“No biodistribution studies with JCAR017 were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 38Source ↗
Modality-specific risk
Insertional mutagenesis/oncogenic transformation from lentiviral transduction; no preferential integration found
“The risk of insertional mutagenesis with lentiviral transduction of the T cells, leading to malignant transformation, was studied using unbiased, genome-wide bioinformatics methods.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Anti-drug antibodies: animals
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Anti-drug antibodies: patients
Treatment-induced or boosted anti-product antibodies 1% to 24% across studies (11% in LBCL cohort); no overall incidence
“Treatment-induced or treatment-boosted anti-product antibodies were detected in 11% (27/257) in Study 3 - LBCL Cohort, 1% (1/89) in Study 1, 2% (1/49) in Study 2, 7% (6/84) in Study 4, 24% (25/103) in Study 5 - FL Cohort, 18% (15/85) in Study 3 - MCL Cohort, and 20% (13/66) in Study 5 - MZL Cohort of patients.”